SGMO SANGAMO THERAPEUTICS, INC

Nasdaq sangamo.com


$ 0.48 $ 0.01 (2.45 %)    

Friday, 07-Nov-2025 18:15:40 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 0.4718
$ 0.46
$ 0.46 x 500
$ 0.53 x 1,000
$ 0.45 - $ 0.50
$ 0.41 - $ 3.18
6,071,760
na
158.76M
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-13-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-08-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 02-24-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-05-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 02-28-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 02-28-2017 12-31-2016 10-K
37 10-27-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-18-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-downgrades-sangamo-therapeutics-to-equal-weight-lowers-price-target-to-1

Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the pric...

 sangamo-therapeutics-q3-eps-011-misses-001-estimate-sales-581000k-miss-34400m-estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate o...

 on-september-9-sangamo-therapeutics-cfo-prathyusha-duraibabu-resigned

-SEC Filing

 hc-wainwright--co-reiterates-buy-on-sangamo-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $...

 sangamo-therapeutics-q2-eps-008-misses-005-estimate-sales-18306m-miss-31680m-estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate o...

Core News & Articles

https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research

 hc-wainwright--co-reiterates-buy-on-sangamo-therapeutics-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 ...

 sangamo-therapeutics-announces-topline-results-from-registrational-phase-12-staar-of-st-920-in-fabry-disease-intends-to-submit-biologics-license-application-in-2026

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dose...

 barclays-maintains-overweight-on-sangamo-therapeutics-lowers-price-target-to-5

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $...

 us-stocks-likely-to-open-lower-after-a-strong-rally-lows-are-likely-in-and-better-times-are-coming-says-expert

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in pr...

 sangamo-therapeutics-q1-eps-014-misses-013-estimate-sales-644m-miss-742m-estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate o...

 sangamo-therapeutics-prices-23m-underwritten-offering-of-12235m-shares-of-common-stock-and-pre-funded-warrants-at-050-and-049-respectively-including-accompanying-warrants-exercisable-at-075

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering c...

 sangamo-therapeutics-q1-gaap-eps-014-misses-013-estimate-sales-644m-miss-742m-estimate

Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION